United Therapeutics shares have sunk to $308.27, producing a disappointing 14% loss - worse than the S&P 500’s 1.4% drop.

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

JACKSONVILLE, Fla., October 23, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, and its subsidiary Lung Bioengineering Inc. (LBE) announced that the 500th lung ...

United Therapeutics’ key phase III programs include Tyvaso in patients with various forms of chronic fibrosing interstitial lung disease (TETON studies) and oral ralinepag in PAH indications ...

United Therapeutics Corporation beats earnings expectations ... And at the International Society for Heart and Lung Transplantation Conference in Boston on April twenty-seventh to the thirtieth.

United Therapeutics’ UTHR fourth-quarter 2024 ... for PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD) indications. Tyvaso DPI recorded sales of $273.2 million ...